Could a shorter TB course work for those with unclear test results?

NCT ID NCT07163143

Not yet recruiting Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at people who have TB-like changes on chest X-rays but negative sputum tests. It compares different treatment lengths (8 to 24 weeks) versus close monitoring without immediate treatment. The goal is to find the shortest effective treatment and understand who really needs it. About 784 participants will be followed for 78 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (standard TB drugs)
What this could lead to: If successful, this could show that a shorter course of TB drugs (8 weeks instead of 24) is just as effective for people with unclear TB, reducing treatment burden.
What could go wrong: This is a Phase 3 trial, but it's still early. The shorter treatment might not work as well, and some people may need longer therapy. Also, the deferred monitoring group carries a risk of disease progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTERIOLOGICALLY UNCONFIRMED PULMONARY TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS (TB)

Contacts and locations

Locations

Bulawayo City Health

Bulawayo, Zimbabwe
Clinical HIV Research Unit, Wits Health Consortium

Johannesburg, South Africa
National University of Medical Sciences

Islamabad, Pakistan
The Aurum Institute

Johannesburg, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.